These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1531968)

  • 1. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor.
    Rupp H; Elimban V; Dhalla NS
    FASEB J; 1992 Mar; 6(6):2349-53. PubMed ID: 1531968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etomoxir improves left ventricular performance of pressure-overloaded rat heart.
    Turcani M; Rupp H
    Circulation; 1997 Nov; 96(10):3681-6. PubMed ID: 9396471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure.
    Rupp H; Vetter R
    Br J Pharmacol; 2000 Dec; 131(8):1748-56. PubMed ID: 11139455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of heart function and Na+-K+-ATPase activity by etomoxir in diabetic rats.
    Kato K; Chapman DC; Rupp H; Lukas A; Dhalla NS
    J Appl Physiol (1985); 1999 Mar; 86(3):812-8. PubMed ID: 10066690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir.
    Rupp H; Schulze W; Vetter R
    Am J Physiol; 1995 Sep; 269(3 Pt 2):R630-40. PubMed ID: 7573566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of myosin isozymes and SR Ca(2+)-pump ATPase of the diabetic rat heart by lipid-lowering interventions.
    Rupp H; Elimban V; Dhalla NS
    Mol Cell Biochem; 1994 Mar; 132(1):69-80. PubMed ID: 8078510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of left ventricular hypertrophy by chronic etomixir treatment.
    Turcani M; Rupp H
    Br J Pharmacol; 1999 Jan; 126(2):501-7. PubMed ID: 10077244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload.
    Dhalla NS; Golfman L; Liu X; Sasaki H; Elimban V; Rupp H
    Ann N Y Acad Sci; 1999 Jun; 874():100-10. PubMed ID: 10415524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins.
    Vetter R; Rupp H
    Am J Physiol; 1994 Dec; 267(6 Pt 2):H2091-9. PubMed ID: 7810710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir.
    Zarain-Herzberg A; Rupp H; Elimban V; Dhalla NS
    FASEB J; 1996 Sep; 10(11):1303-9. PubMed ID: 8836044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential influences of carnitine palmitoyltransferase-1 inhibition and hyperthyroidism on cardiac growth and sarcoplasmic reticulum phosphorylation.
    Vetter R; Kott M; Rupp H
    Eur Heart J; 1995 May; 16 Suppl C():15-9. PubMed ID: 7556265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target.
    Zarain-Herzberg A; Rupp H
    Expert Opin Investig Drugs; 2002 Mar; 11(3):345-56. PubMed ID: 11866664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo.
    Schwarzer M; Faerber G; Rueckauer T; Blum D; Pytel G; Mohr FW; Doenst T
    Basic Res Cardiol; 2009 Sep; 104(5):547-57. PubMed ID: 19294446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial contractility after infarction and carnitine palmitoyltransferase I inhibition in rats.
    Günther J; Wagner K; Theres H; Schimke I; Born A; Scholz H; Vetter R
    Eur J Pharmacol; 2000 Oct; 406(1):123-6. PubMed ID: 11011043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir.
    Schmitz FJ; Rösen P; Reinauer H
    Horm Metab Res; 1995 Dec; 27(12):515-22. PubMed ID: 8750778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir.
    Lopaschuk GD; McNeil GF; McVeigh JJ
    Mol Cell Biochem; 1989 Jun 27-Jul 24; 88(1-2):175-9. PubMed ID: 2779537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolically-modulated growth and phenotype of the rat heart.
    Rupp H; Jacob R
    Eur Heart J; 1992 Sep; 13 Suppl D():56-61. PubMed ID: 1396861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum.
    Rupp H; Wahl R; Hansen M
    J Appl Physiol (1985); 1992 Jan; 72(1):352-60. PubMed ID: 1537736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of carnitine palmitoyltransferase 1 by phenylalkyloxiranecarboxylic acid and its influence on lipolysis and glucose metabolism in isolated, perfused hearts of streptozotocin-diabetic rats.
    Rösen P; Reinauer H
    Metabolism; 1984 Feb; 33(2):177-85. PubMed ID: 6694560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy.
    Hülsmann WC; Peschechera A; Schneijdenberg CT; Verkleij AJ
    Cardioscience; 1994 Sep; 5(3):193-7. PubMed ID: 7827256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.